

July 7, 2011

Hello,

I am pleased to inform you that the pan-Canadian Oncology Drug Review (pCODR) will begin accepting submissions on July 13, 2011, thus completing the evolution from the interim Joint Oncology Drug Review (iJODR). The purpose of this letter is to advise you of the short-term transition plan and to provide you with information on how patient advocacy groups can contribute to the pCODR review process.

A short-term transition plan has been developed to ensure there is no disruption in the review of submissions. During the first month that pCODR begins to accept submissions, submitters will have the choice to submit through either the interim Joint Oncology Drug Review (iJODR) or the pCODR review processes. Once the review stream has been selected, the submitter must meet the submission requirements for their selected review process and the review will need to continue through that stream. The last day to submit a submission through the iJODR process will be August 12, 2011. As of August 15, 2011 all submissions that fit under pCODR's mandate must go through the pCODR process.

In order for patient advocacy groups to contribute to the pCODR drug review process they must be registered with pCODR. To register please visit the Submit and Contribute section of the pCODR web site (www.pcodr.ca). Once registered, patient advocacy groups will be notified of a pending drug submission and invited to provide relevant information. Information about providing patient input is available in the Patient Engagement Guide under Our Review Process on the pCODR website (Step 3.2).

The transition from iJODR to pCODR has required the efforts of many people. I appreciate the contributions and commitment of patient advocacy groups, pharmaceutical manufacturers and governments from across Canada. I look forward to our continued work together.

Sincerely,



Mona Sabharwal
Executive Director

cc: pCODR Steering Committee